Eczema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Your doctor has decided that starting treatment with nemolizumab (Nemluvio®) is right for you, following the approved guidelines for this medicine.
- You are aged 12 or older and have been diagnosed with moderate-to-severe atopic dermatitis (eczema).
- You (or your legal guardian) have read and signed the consent form agreeing to take part in the study.
Who may not be able to join:
- You have a medical reason why you should not take nemolizumab (Nemluvio®), based on the official guidelines for this medicine.
- You have taken part in a study using another experimental drug or treatment within the last 3 months before the start of this trial.
- You have previously received nemolizumab at any point in the past.
- You are unable to understand the consent form or complete the study questionnaires due to mental, physical, or language barriers.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 817-961-5000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Investigator Global Assessment (IGA) at Month 6; Peak Pruritus Numerical Rating Scale (PP NRS) at Month 6
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.